• 1
    US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2008 Incidence and Mortality Web-based Report. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2012.
  • 2
    Singh GK, Miller BA, Hankey BF, Edwards BK. Persistent area socioeconomic disparities in US incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer. 2004;101:1051-1057.
  • 3
    Watson M, Saraiya M, Benard V, et al. Burden of cervical cancer in the US, 1998-2003. Cancer. 2008;113(10 suppl):2855-2864.
  • 4
    Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
  • 5
    Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36:6-10.
  • 6
    Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(suppl 3):S3/1-S3/30.
  • 7
    Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-632.
  • 8
    Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:626-629.
  • 9
    Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta D, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine. 2010;28:4731-4737.
  • 10
    Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California Public Family Planning Administrative Claims Data, 2007-2010. Am J Public Health. 2012;102:833-835.
  • 11
    Brotherton JML, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological analysis. Lancet. 2011;377:2085-2092.
  • 12
    Leval A, Herweijer E, Arnheim-Dahlström L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012;206:860-866.
  • 13
    de Sanjose S, Quint WG, Alemany L, et al; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-1056.
  • 14
    Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131:2349-2359.
  • 15
    Li N, Franceschi S, Howell-Jones R, Snijders PJF, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancer worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128:927-935.
  • 16
    Schiffman M, Castle PE, Jeronimo J, Rodriquez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907.
  • 17
    Wheeler CM. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer. Obstet Gynecol Clin N Am. 2008;35:519-536.
  • 18
    Coutlee F, Ratnam S, Ramanakumar AV, et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol. 2011;83:1034-1041.
  • 19
    Hariri S, Unger ER, Powell SE, et al. Human papillomavirus genotypes in high grade cervical lesions in the United States. J Infect Dis. 2012;206:1878-1886.
  • 20
    Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2008;17:1611-1622.
  • 21
    Krieger N, Chen JT, Waterman PD, Rehkoph DH, Subramanian SV. Painting a truer picture of US socioeconomic and racial/ethnic health inequalities: the Public Health Disparities Geocoding Project. Am J Public Health. 2005;95:312-323.
  • 22
    Hariri S, Unger ER, Powell SE, et al. The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes Control. 2012;23:281-288.
  • 23
    Niccolai LM, Julian PJ, Bilinski A, et al. Area-based poverty, racial, and ethnic disparities in cervical cancer precursor rates in Connecticut, 2008-2009. Am J Public Health. 2013;103:156-163.
  • 24
    Krieger N, Chen JT, Waterman PD, Soobader MJ, Subramanian SV, Carson R. Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographical level matter? Am J Epidemiol. 2002;156:471-482.
  • 25
    Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690-1691.
  • 26
    Krieger N. Why epidemiologists cannot afford to ignore poverty. Epidemiology. 2007;18:658-663.
  • 27
    Coughlin SS, King J, Richards TB, Ekwueme DU. Cervical cancer screening among women living in metropolitan areas of the United States by individual-level and area-based measures of socioeconomic status, 200 to 2002. Cancer Epidemiol Biomarkers Prev. 2006;15:2154-2159.
  • 28
    Simard EP, Fedewa S, Ma J, Siegel R, Jemal A. Widening socioeconomic disparities in cervical cancer mortality among women in 26 states, 1993-1997. Cancer. 2012;118:5110-5116.
  • 29
    Vinokurova S, Wentzensen N, Kraus I, et al. Type dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008;68:307-313.
  • 30
    Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis. 2009;200:166-171.
  • 31
    Tumban E, Peabody J, Peabody DS, Chackerian B. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One. 2011;6:e23310.